The board of directors of Simcere Pharmaceutical Group Limited announced that on April 27, 2023, the new indication of intracerebral hemorrhage (ICH) of Sanbexin®? (Edaravone and Dexborneol Concentrated Solution for Injection), an innovative drug of the Group, has obtained the clinical trial approval issued by the National Medical Products Administration of the PRC, which is intended for the multi-center, randomized, double-blind and placebo-controlled phase II clinical trial to evaluate the efficacy and safety of Edaravone and DexborneOL Concentrated Solution for Injection with different dosages in combination of conventional medical therapies to treat ICH patients. Sanbexin®?

was recommended by multiple guidelines and consensus such as the Specialists' Consensus on the Clinical Assessment and Treatment of Acute Cerebral Infarction Ischemic Penumbra in China ), and multiple relevant studies were presented at the European Stroke Organization Conference (ESOC), the scientific meeting of the American Heart Association (AHA) Hypertension Council, and the World Congress of Neurology (WCN).